A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

135

Participants

Timeline

Start Date

June 17, 2019

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2026

Conditions
Advanced CancerLymphomaSolid TumorMelanoma
Interventions
DRUG

NUC-7738

NUC-7738

DRUG

Pembrolizumab

Pembrolizumab

Trial Locations (9)

CB2 0QQ

NOT_YET_RECRUITING

Cambridge University Hospitals NHS Foundation Trust (Addenbrookes Hospital), Cambridge

EH4 2XU

RECRUITING

Edinburgh Cancer Centre, Western General Hospital, Edinburgh

G12 0TN

RECRUITING

The Beatson West of Scotland Cancer Centre, Glasgow

NW1 2PG

NOT_YET_RECRUITING

University College London Hospital, London

SW3 6JJ

NOT_YET_RECRUITING

The Royal Marsden NHS Foundation Trust, London

M20 4BX

RECRUITING

The Christie NHS Foundation Trust, Manchester

NE7 7DN

RECRUITING

Freeman Hospital, Newcastle

OX3 9DU

RECRUITING

Oxford University Hospitals NHS Foundation Trust, Oxford

PR2 9HT

NOT_YET_RECRUITING

Lancashire Teaching Hospitals NHS Foundation Trust, Royal Preston Hospital, Preston

Sponsors

Lead Sponsor

All Listed Sponsors
lead

NuCana plc

OTHER

NCT03829254 - A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma | Biotech Hunter | Biotech Hunter